Early attendance numbers show ATS 2016 in San Francisco, California, is a popular destination. As of Monday afternoon, there were more than 17,000 registered attendees from 90 countries.

Katie Meyler will share the story of her compelling work as one of the “Ebola Fighters,” collectively recognized by TIME magazine as the 2014 Person of the Year, during the Plenary Session on Tuesday. At the onset of the largest Ebola epidemic in history, Ms. Meyler was spurred to turn her school for girls in Liberia into a disaster-response center.

Tuesday’s Keynote Series presentations will examine chronic obstructive pulmonary disease (COPD) and G-protein coupled receptor (GPCR) signaling. Presenters on Wednesday will cover biomarkers for precision medicine in asthma and acute respiratory distress syndrome (ARDS). The lectures will be given concurrently from 8 to 8:45 a.m.

An interview with David Gozal, MD, ATS President-Elect.

Three exhibitors will share unique ways in which they endeavor to raise awareness about devastating lung diseases. From the storytelling and artistry of patients, to a documentary film memorializing an actor, to a patient who ran in Bay to Breakers 2016 during the conference, the companies will show how these individuals are not defined by their lung disease diagnoses.

Until recently, primary ciliary dyskinesia (PCD) has received little attention or research funding.

Recent studies are making many researchers re-evaluate long-standing ideas on the development of chronic obstructive pulmonary disease. An ATS mythbusters symposium on Wednesday will examine the emerging theory that the alteration of lung tissue regeneration, not inflammation, plays a driving role in the pathogenesis of COPD.

A battle over climate change is brewing in U.S. courts, and the ATS is fighting for the health of our patients.